Neurocrine Biosciences, Inc.
NASDAQ:NBIXBiotechnology
-$0.71 today
- Market cap
- $16.48B
- Beta
- 0.40
- P/E (TTM)
- 23.8
- EPS (TTM)
- $6.65
Volume 1.60M
Average 1.18M
NBIX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Neurocrine Biosciences, Inc.NASDAQ: NBIX
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $351.8M rose 40.7% year over year, ahead of the +30.7% change in trailing-twelve-month research & development. Sequentially, it rose 7.7% from the prior quarter. Over 3 fiscal years it compounded at +29.9% a year.
Context
- Research & development amounted to 35.5% of revenue in FY2025, up 4.5 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +40.7% holds above the trailing-twelve-month pace of +30.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 1.02B USD
- Year-over-year change
- +38.9%
- 4-year CAGR
- +32.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.02B | +38.9% |
| FY2024 | 2024-12-31 | 731.1M | +29.4% |
| FY2023 | 2023-12-31 | 565M | +21.8% |
| FY2022 | 2022-12-31 | 463.8M | +41.4% |
| FY2021 | 2021-12-31 | 328.1M | — |
Research & Development vs competitors
How NBIX compares with its peers on the latest reported figures
- NBIX's LTM Sep 2026 research & development of $1.23B is the highest of the 10 companies compared; the peer median is $162.51M.
- Its year-over-year change of +30.7% is the 2nd highest of 10, against a peer median of -3.5%.
- Research & development amounts to 33.3% of revenue for NBIX, versus a peer median of 25.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.23B | +30.7% | +29.9% | 33.3% | |
| LTM Sep 2026 | $623.61M | -26.8% | +9.9% | 13.2% | |
| LTM Jun 2026 | $467.76M | -32.9% | +13.3% | — | |
| LTM Sep 2026 | $319.46M | -7.3% | -3.1% | 26.6% | |
| LTM Jun 2026 | $187.86M | -3.5% | +46.8% | 24.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M | -21.6% | +18.9% | — |
| LTM Jun 2026 | $126.09M | +18.1% | +12.5% | 15.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.93M | +58.7% | +118.3% | 539.7% |
| LTM Mar 2026 | $101.99M | +14.6% | +8.4% | 46.8% | |
| LTM Mar 2026 | $43.27M | +26.5% | +23.7% | — | |
| Peer median (excluding NBIX) | $162.51M | -3.5% | +13.3% | 25.4% | |
Competitors are the stored peer set for NBIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.13B | 1.49B | 1.89B | 2.36B | 2.86B |
| Cost of Revenue | 14.3M | 23.2M | 39.7M | 34M | 52.1M |
| Gross Profit | 1.12B | 1.47B | 1.85B | 2.32B | 2.81B |
| Gross Margin | 98.7% | 98.4% | 97.9% | 98.6% | 98.2% |
| Research & Development | 328.1M | 463.8M | 565M | 731.1M | 1.02B |
| Selling, General & Admin | 583.3M | 752.7M | 887.6M | 1.01B | 1.16B |
| Operating Expenses | 1.02B | 1.22B | 1.6B | 1.75B | 2.19B |
| Depreciation & Amortization | 10.9M | 15.6M | 21.3M | 27.1M | 30.1M |
| EBITDA | 138.1M | 236.6M | 416.1M | 639.7M | 666.6M |
| EBITDA Margin | 12.2% | 15.9% | 22.0% | 27.2% | 23.3% |
| Operating Income | 102.5M | 249M | 250.9M | 570.5M | 619.1M |
| Operating Margin | 9.0% | 16.7% | 13.3% | 24.2% | 21.6% |
| Interest Income | 0 | 11.2M | 0 | 91M | 90.3M |
| Interest Expense | 25.8M | 7.1M | 4.6M | 126.6M | 0 |
| Other Income / Expenses | (1.1M) | (35.1M) | 81.2M | (84.5M) | 86.3M |
| Income Before Tax | 101.4M | 213.9M | 332.1M | 486M | 705.4M |
| Pre-Tax Margin | 8.9% | 14.4% | 17.6% | 20.6% | 24.7% |
| Income Tax Expense | 11.8M | 59.4M | 82.4M | 144.7M | 226.8M |
| Net Income | 89.6M | 154.5M | 249.7M | 341.3M | 478.6M |
| Net Margin | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% |
| EPS (Basic) | 0.95 | 1.61 | 2.56 | 3.40 | 4.81 |
| EPS (Diluted) | 0.92 | 1.56 | 2.47 | 3.29 | 4.67 |
| Weighted Avg Shares | 94.6M | 95.8M | 97.7M | 100.4M | 99.5M |
| Weighted Avg Shares (Diluted) | 97.9M | 98.9M | 101M | 103.7M | 102.5M |
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
Intrinsic Alpha fair value
Locked
Current Price
$162.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.